QT Guidance Reducing Number Of Drugs Leaving Early Development, Firms Say

Stricter guidelines on QT prolongation are forcing manufacturers to drop compounds earlier in the development process, participants said during an FDA/Duke Cardiac Safety and Critical Path Initiative Think Tank meeting Oct. 11